Is Tafasitamab on the market?

AntiCD19 monoclonal antibody tafasitamab combined with lenalidomide (LEN) for relapsed or refractory (R/R) diffuse large B cells not suitable for transplantation Lymphoma (DLBCL) patients received accelerated marketing approval from the U.S. Food and Drug Administration (FDA) in July 2020 in the United States, marketing approval in Europe in August 2021, and may also obtain conditional marketing approval in other overseas countries.

Patients with diffuse large-cell lymphoma whose cancer has recurred or is unresponsive to treatment and who are ineligible for autologous stem cell transplantation have limited treatment options. The combination of tafracetamumab and lenalidomide was shown to provide clinically meaningful responses with manageable side effects. The recommended dose of tafracetamumab is intravenous infusion of 12 mg/kg in combination with lenalidomide 25 mg for 12 cycles, followed by tafracetamumab monotherapy until disease progression or unacceptable toxicity. Tafaracetam plus LEN is associated with durable responses in patients with R/R DLBCL.

Talfaracetam's single-origin generic drug has not yet been launched in the country, so it is not included in medical insurance. There are European and American versions of Tafaracetam's single-antigen drugs marketed overseas. The American version's specificationsThe price per box of 200 mg may be around 20,000 yuan, and the price of the European version's 200 mg box may be around 10,000 yuan (the price may fluctuate due to exchange rates). The ingredients of the two drugs are basically the same, but the price is more expensive. Currently, there is no generic version of Tafaracetam on the market. For more drug information and specific prices, please consult a medical consultant.